Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae: Risk Factors, Molecular Epidemiology, and Clinical Outcome

ABSTRACT Bloodstream infections caused by extended-spectrum-β-lactamase (ESBL)-producing Klebsiella pneumoniae isolates are a major concern for clinicians, since they markedly increase the rates of treatment failure and death. One hundred forty-seven patients with K. pneumoniae bloodstream infections were identified over a 5-year period (January 1999 to December 2003). The production of ESBLs in bloodstream isolates was evaluated by molecular methods. A retrospective case-case-control study was conducted to identify risk factors for the isolation of ESBL-producing K. pneumoniae or non-ESBL-producing K. pneumoniae isolates in blood cultures. Forty-eight cases infected with ESBL-producing K. pneumoniae isolates and 99 cases infected with non-ESBL-producing K. pneumoniae isolates were compared to controls. Risk factors for isolation of ESBL-producing K. pneumoniae isolates were exposure to antibiotic therapy (odds ratio [OR], 11.81; 95% confidence interval [CI], 2.72 to 51.08), age (OR, 1.14; 95% CI, 1.08 to 1.21), and length of hospitalization (OR, 1.10; 95% CI, 1.04 to 1.16). Independent determinants for isolation of non-ESBL-producing K. pneumoniae were previous urinary tract infection (OR, 8.50; 95% CI, 3.69 to 19.54) and length of hospitalization (OR, 1.07; 95% CI, 1.04 to 1.10). When the initial response was assessed at 72 h after antimicrobial therapy, the treatment failure rate for the ESBL-producing K. pneumoniae-infected group was almost twice as high as that of the non-ESBL-producing K. pneumoniae-infected group (31% versus 17%; OR, 2.19; 95% CI, 0.98 to 4.89). The 21-day mortality rate for all patients was 37% (54 of 147); it was 52% (25 of 48) for patients with ESBL-producing K. pneumoniae bloodstream infections and 29% (29 of 99) for patients with non-ESBL-producing K. pneumoniae bloodstream infections (OR, 2.62; 95% CI, 1.28 to 5.35). In summary, this investigation identifies epidemiological characteristics that distinguish ESBL-producing K. pneumoniae infections from non-ESBL-producing K. pneumoniae ESBL bloodstream infections.

[1]  W. Bilker,et al.  Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. , 2005, Archives of internal medicine.

[2]  Neil Woodford,et al.  Outbreak of Klebsiella pneumoniae Producing a New Carbapenem-Hydrolyzing Class A β-Lactamase, KPC-3, in a New York Medical Center , 2004, Antimicrobial Agents and Chemotherapy.

[3]  Sung-Han Kim,et al.  Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Mortality and Treatment Outcome, with Special Emphasis on Antimicrobial Therapy , 2004, Antimicrobial Agents and Chemotherapy.

[4]  D. Sandvang,et al.  Increased Serum Resistance in Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases , 2004, Antimicrobial Agents and Chemotherapy.

[5]  S. Pértega,et al.  Risk Factors for Colonization and Infection in a Hospital Outbreak Caused by a Strain of Klebsiella pneumoniae with Reduced Susceptibility to Expanded-Spectrum Cephalosporins , 2004, Journal of Clinical Microbiology.

[6]  Geun Ho Kang,et al.  Molecular Characterization of Extended-Spectrum Beta-Lactamases Produced by Clinical Isolates of Klebsiella pneumoniae and Escherichia coli from a Korean Nationwide Survey , 2004, Journal of Clinical Microbiology.

[7]  M. Mulvey,et al.  Ambler Class A Extended-Spectrum Beta-Lactamase-Producing Escherichia coli and Klebsiella spp. in Canadian Hospitals , 2004, Antimicrobial Agents and Chemotherapy.

[8]  H. Goossens,et al.  International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum -Lactamase Production in Nosocomial Infections , 2004, Annals of Internal Medicine.

[9]  M. Pimkin,et al.  Prevalence and Molecular Epidemiology of CTX-M Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in Russian Hospitals , 2003, Antimicrobial Agents and Chemotherapy.

[10]  L. Rice,et al.  Extended-Spectrum β-Lactamases in Klebsiella pneumoniae Bloodstream Isolates from Seven Countries: Dominance and Widespread Prevalence of SHV- and CTX-M-Type β-Lactamases , 2003, Antimicrobial Agents and Chemotherapy.

[11]  Jeannie P. Cimiotti,et al.  Attributable Costs and Length of Stay of an Extended-Spectrum Beta-Lactamase-Producing Klebsiella pneumoniae Outbreak in a Neonatal Intensive Care Unit , 2003, Infection Control & Hospital Epidemiology.

[12]  Maurizio Sanguinetti,et al.  Characterization of Clinical Isolates of Enterobacteriaceae from Italy by the BD Phoenix Extended-Spectrum β-Lactamase Detection Method , 2003, Journal of Clinical Microbiology.

[13]  Dechang Chen,et al.  Extended-spectrum beta-lactamase-producing Escherichiacoli and Klebsiellapneumoniae bloodstream infection: risk factors and clinical outcome , 2002, Intensive Care Medicine.

[14]  P. Bradford,et al.  Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. Patel,et al.  Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella Species: Risk Factors for Colonization and Impact of Antimicrobial Formulary Interventions on Colonization Prevalence , 2002, Infection Control & Hospital Epidemiology.

[16]  G. Rossolini,et al.  Molecular Characterization of Extended-Spectrum β-Lactamases Produced by Nosocomial Isolates of Enterobacteriaceae from an Italian Nationwide Survey , 2002, Journal of Clinical Microbiology.

[17]  G. Fadda,et al.  Occurrence of Extended-Spectrum β-Lactamases in Members of the Family Enterobacteriaceae in Italy: Implications for Resistance to β-Lactams and Other Antimicrobial Drugs , 2002, Antimicrobial Agents and Chemotherapy.

[18]  J. Quinn,et al.  Extended‐Spectrum β‐Lactamases: Frequency, Risk Factors, and Outcomes , 2002, Pharmacotherapy.

[19]  P. Bradford.  Extended-Spectrum β-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat , 2001, Clinical Microbiology Reviews.

[20]  Victor L. Yu,et al.  Outcome of Cephalosporin Treatment for Serious Infections Due to Apparently Susceptible Organisms Producing Extended-Spectrum β-Lactamases: Implications for the Clinical Microbiology Laboratory , 2001, Journal of Clinical Microbiology.

[21]  R. Cantón,et al.  Variations in the prevalence of strains expressing an extended-spectrum beta-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  Y. Carmeli,et al.  Methodological principles of case-control studies that analyzed risk factors for antibiotic resistance: a systematic review. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  G. Eliopoulos,et al.  New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Karlowsky,et al.  Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance , 2001, Antimicrobial Agents and Chemotherapy.

[26]  P. Fey,et al.  Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  Anthony D. Harris,et al.  Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant Escherichia coli in Hospitalized Patients , 2000, Antimicrobial Agents and Chemotherapy.

[28]  H. Goossens,et al.  Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  D. Livermore,et al.  Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. , 2000, The Journal of antimicrobial chemotherapy.

[30]  R. Podschun,et al.  Klebsiella spp. as Nosocomial Pathogens: Epidemiology, Taxonomy, Typing Methods, and Pathogenicity Factors , 1998, Clinical Microbiology Reviews.

[31]  M. Samore,et al.  The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum β-lactamase in a tertiary care hospital* , 1998 .

[32]  P. Gerner-Smidt,et al.  Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the Acinetobacter calcoaceticus-Acinetobacter baumannii complex and application of the method to the investigation of a hospital outbreak , 1996, Journal of clinical microbiology.

[33]  R. Labia,et al.  Survey of Klebsiella pneumoniae producing extended-spectrum beta-lactamases: prevalence of TEM-3 and first identification of TEM-26 in France , 1996, Antimicrobial agents and chemotherapy.

[34]  D. Livermore.  beta-Lactamases in laboratory and clinical resistance , 1995, Clinical microbiology reviews.

[35]  P. Hawkey,et al.  Convergent evolution of TEM-26, a β-lactamase with extended-spectrum activity , 1994 .

[36]  W. Knaus.  The APACHE III Prognostic System , 1992 .

[37]  R. Labia,et al.  Does high level production of SHV-type penicillinase confer resistance to ceftazidime in Enterobacteriaceae? , 1992, FEMS microbiology letters.

[38]  W. Knaus,et al.  The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. , 1991, Chest.

[39]  T. Sirakova,et al.  Characterization of PPD protein antigens in whole cell lysates of Mycobacterium bovis BCG. , 1990, FEMS microbiology letters.

[40]  B. Yangco,et al.  CDC definitions for nosocomial infections. , 1989, American journal of infection control.

[41]  J M Hughes,et al.  CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.

[42]  S. Mitsuhashi,et al.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens , 1983, Infection.

[43]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[44]  H. Goossens,et al.  INTERNATIONAL PRASPECTIVE STUDY OF KLEBSIELLA PNEUMONIAE IN NOSOCOMIAL BACTEREMIA:IMPLICATIONS OF EXTENDEDSPECTERUM- BETA LACTAMASE PRODUCTION IN NOSOCOMIAL INFECTIONS , 2004 .

[45]  J. Quinn,et al.  Extended-spectrum beta-lactamases: frequency, risk factors, and outcomes. , 2002, Pharmacotherapy.

[46]  K. Riesenberg,et al.  Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. , 2001, Scandinavian journal of infectious diseases.

[47]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .

[48]  M. Samore,et al.  The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. , 1998, The Journal of infection.

[49]  J. Heritage,et al.  Convergent evolution of TEM-26, a beta-lactamase with extended-spectrum activity. , 1994, The Journal of antimicrobial chemotherapy.

[50]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[51]  Robert Theodore Wurtz.  Précis de Bactériologie clinique , 1895 .